Michel Baijot
Director/Board Member at DMS IMAGING
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Frank Hazevoets | M | 57 | 5 years | |
| Hilde Windels | F | 59 |
Antelope Dx BV
 Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | 5 years |
| Jan-Willem Hoste | M | - |
Antelope Dx BV
Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | 5 years |
| Ralph Leijenaar | M | - |
OncoRadiomics SA
 OncoRadiomics SA Investment Trusts/Mutual FundsMiscellaneous OncoRadiomics SA functions as a foundation or endowment. Its products include radiomix, distrim and virtual patient auatar. The company was founded by Ralph Leijenaar, Sean Walsh and Tulcinsky Paul on September 19, 2016 and is headquartered in Liège, Belgium. | 8 years |
| Vincent Bille | M | - | - | |
| François Fontaine | M | - |
White Fund SA
 White Fund SA Investment ManagersFinance White Fund SA invests in companies located in Belgium and possibly neighbouring regions. It targets companies operating in the medical device sector. It provides financing for early stage with an investment size ranging between €2 million and €5 million per project. Exits are targeted after 5-7 years. | - |
| Jean-Paul Ansel | M | 74 | 2 years | |
| Béatrice de Vos | M | - |
GlaxoSmithKline Biologicals NV
 GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | 9 years |
| Sean Walsh | M | - |
OncoRadiomics SA
OncoRadiomics SA Investment Trusts/Mutual FundsMiscellaneous OncoRadiomics SA functions as a foundation or endowment. Its products include radiomix, distrim and virtual patient auatar. The company was founded by Ralph Leijenaar, Sean Walsh and Tulcinsky Paul on September 19, 2016 and is headquartered in Liège, Belgium. | 8 years |
| Swan Tuffery | M | - | - | |
| Delphine de Courson | F | - | - | |
| Nathalie Caire Richard | F | - | - | |
| Marcel van Kasteel | M | - |
Antelope Dx BV
Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | - |
| Ana Maricevic | F | - |
Antelope Dx BV
Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | - |
| Hugues Wallemacq | M | - |
Antelope Dx BV
Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | - |
| Rudi de Winter | M | 63 |
Antelope Dx BV
Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | - |
| Martine Draguet | M | - | 10 years | |
| Philippe Ghem | M | - | - | |
| Rudi Mariën | M | 79 |
Antelope Dx BV
Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | - |
| François Meurgey | M | - | 11 years | |
| Philippe Degeer | M | 61 | - | |
| Samuel Sancerni | M | - | - | |
| Firdaus Jal Dastoor | M | 72 |
Serum Institute of India Pvt Ltd.
 Serum Institute of India Pvt Ltd. BiotechnologyHealth Technology Serum Institute of India Pvt Ltd. engages in the production and exportation of anti-cancer products and viral vaccines. Its products include bacterial vaccines, recombinant and combination vaccines, viral vaccines, influenza vaccines. uro-oncology, and polysaccharide conjugate vaccine. The company was founded by Cyrus S. Poonawalla in 1966 and is headquartered in Pune, India. | 8 years |
| Luc Osselaer | M | 60 |
Antelope Dx BV
Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | - |
| Louise Armengaud | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Yves Jean Marie Désiront | M | 53 | 7 years | |
| Gerd Zettlmeissl | M | 68 | 7 years | |
| Jean-Paul Prieels | M | 78 |
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | 26 years |
| Paul Magrez | M | - |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 6 years |
| Frank Morich | M | 69 |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 2 years |
| Jean Duchateau | M | - | 5 years | |
| Harry Welten | M | 59 | - | |
| Lieve Nuytinck | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | - |
| Gilles Della Corte | M | - | - | |
| Marian Nakada | M | - |
Janssen, Inc.
 Janssen, Inc. Pharmaceuticals: MajorHealth Technology Janssen, Inc. operates as a pharmaceutical company of Johnson & Johnson. Its products include Caelyx, Concerta, Cyclen, Ditropan XL, Duragesic, Edurant, Evra, Galexos, Invega, Invokana, Jurnista, Livostin, Pariet, Remicade, Sylvant, Topamax, Ultram, Velcade, Yondelis, and Zytiga. The company is headquartered in Toronto, Canada. | 4 years |
| James Tursi | M | 59 |
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | 3 years |
| Filip Goossens | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 6 years |
| Vera Goossens | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 5 years |
| Marc van Dijk | M | 61 |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 3 years |
| Louis Champion | M | 64 | 2 years | |
| Duane A. Morris | M | 74 |
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | 1 years |
| George Lowell | M | 78 |
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | 1 years |
| Adrian Rawcliffe | M | 52 |
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | - |
| Marie Pierre Beaumont | F | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Belgium | 42 | 95.45% |
| Canada | 1 | 2.27% |
| India | 1 | 2.27% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michel Baijot
- Personal Network
